Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its…
7 analysts rate ANL Buy on consensus.
Consensus price target: $29.50 (+178.83% upside from $10.58)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Ji Ping director | Sep 30, 2026 | Sale | 5,000 | $79.75K |
| Ji Ping director | Sep 30, 2026 | Sale | 5,000 | $80.15K |
| Ji Ping director | Sep 29, 2026 | Sale | 214 | $3.37K |
| Ji Ping director | Sep 22, 2026 | Sale | 5,000 | $83.15K |
| Ye Xiaofeng CFO | Aug 26, 2026 | Sale | 5,667 | $80.75K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $5M | — | $-35.53M |
| 2024 | $0 | — | $-51.87M |
| 2023 | $0 | — | $-109.23M |
Stock data for ANL: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics